Form 4: Processa CFO Russell Skibsted Increases Stake in PCSA

Processa Pharmaceuticals CFO Russell Skibsted acquired 2,190 shares of common stock at $2.69 per share.

Summary

• Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc., purchased 2,190 shares of common stock.
• The transaction occurred on April 30, 2026, at a price of $2.69 per share.
• Following this transaction, the reporting person's total beneficial ownership is 6,498 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive signal, as it reflects internal confidence from the CFO, though the transaction size is relatively small.

Positives

• Insider confidence is demonstrated by the CFO's decision to increase his equity position in the company through an open-market purchase.

Negatives

• None noted.

Risks

• The company is subject to the inherent risks of the pharmaceutical development industry, including clinical trial outcomes and regulatory approval processes.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider buying in small-cap biotech firms is often viewed by the market as a signal of management's belief in the company's pipeline potential or current valuation.

Comparison to Industry Standards

• Insider purchases by C-suite executives are generally viewed as a positive signal compared to neutral or divestment activity in the small-cap pharmaceutical sector.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of management alignment with long-term company performance.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Insider Trading, CFO, Stock Purchase, Biotech